Topics

Insulin glargine biosimilar for diabetes to be launched in Australia

05:51 EDT 4 Oct 2019 | SmartBrief

Biocon and Mylan announced plans to launch a biosimilar of Semglee, or insulin glargine, in Australia as a treatment for pati -More

Original Article: Insulin glargine biosimilar for diabetes to be launched in Australia

NEXT ARTICLE

More From BioPortfolio on "Insulin glargine biosimilar for diabetes to be launched in Australia"

Quick Search

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...